I
Inge J. Stijleman
Researcher at Huntsman Cancer Institute
Publications - 11
Citations - 1253
Inge J. Stijleman is an academic researcher from Huntsman Cancer Institute. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 7, co-authored 11 publications receiving 1109 citations.
Papers
More filters
Journal ArticleDOI
Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes
Yoko S. DeRose,Guoying Wang,Yi Chun Lin,Philip S. Bernard,Saundra S. Buys,Mark T. W. Ebbert,Rachel E. Factor,Cindy B. Matsen,Brett Milash,Edward W. Nelson,Leigh Neumayer,R. Lor Randall,Inge J. Stijleman,Bryan E. Welm,Alana L. Welm +14 more
TL;DR: It is reported that tumor engraftment is a prognostic indicator of disease outcome for women with newly diagnosed breast cancer and orthotopic breast tumor grafting is a step toward individualized models for tumor growth, metastasis and prognosis.
Journal ArticleDOI
PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers
Roy R. L. Bastien,Álvaro Rodríguez-Lescure,Mark T. W. Ebbert,Aleix Prat,Aleix Prat,Blanca Munárriz,Leslie R. Rowe,Patricia Miller,Manuel Ruiz-Borrego,Daniel Anderson,Bradley W. Lyons,Isabel Alvarez,Tracy Dowell,David Wall,Miguel Ángel Seguí,Lee Barley,Kenneth M. Boucher,Emilio Alba,Lisa Pappas,Carole Davis,Ignacio Aranda,Christiane Fauron,Inge J. Stijleman,José Palacios,Antonio Antón,Eva Carrasco,Rosalía Caballero,Matthew J. Ellis,Torsten O. Nielsen,Charles M. Perou,Mark E. Astill,Philip S. Bernard,Philip S. Bernard,Miguel Martin +33 more
TL;DR: The standard immunohistochemical panel for breast cancer (ER, PR, and HER2) does not adequately identify the PAM50 gene expression subtypes and single gene scoring for ESR1, PGR, and ERBB2 was more prognostic than the corresponding IHC markers as shown in a multivariate analysis.
Journal ArticleDOI
Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression
Marilyn L. Kwan,Candyce H. Kroenke,Carol Sweeney,Carol Sweeney,Philip S. Bernard,Erin Weltzien,Adrienne Castillo,Rachel E. Factor,Kaylynn S. Maxfield,Inge J. Stijleman,Lawrence H. Kushi,Charles P. Quesenberry,Laurel A. Habel,Bette J. Caan +13 more
TL;DR: Highly obese patients are more likely to have tumor subtypes associated with high proliferation and poorer prognosis, andER expression may not increase correspondingly with increasing degree of obesity.
Journal ArticleDOI
Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models.
Matthew D. Thompson,Clinton J. Grubbs,Ann M. Bode,Joel M. Reid,Renee M. McGovern,P Bernard,Inge J. Stijleman,Jeffery E. Green,Christina Bennett,M. Margaret Juliana,Fariba Moeinpour,Vernon E. Steele,Ronald A. Lubet +12 more
TL;DR: Metformin did not prevent mammary carcinogenesis in two mammary cancer models, raising questions about metformin efficacy in breast cancer in nondiabetic populations.
Journal ArticleDOI
Characterization of uncertainty in the classification of multivariate assays: Application to PAM50 centroid-based genomic predictors for breast cancer treatment plans
Mark T. W. Ebbert,Mark T. W. Ebbert,Roy R. L. Bastien,Kenneth M. Boucher,Miguel Martin,Eva Carrasco,Rosalía Caballero,Inge J. Stijleman,Philip S. Bernard,Philip S. Bernard,Julio C. Facelli +10 more
TL;DR: It is shown that the PAM50 results are resilient to intrinsic errors within the assay, but also finding that in non-archetypal samples, experimental errors can lead to quite different classification of a tumor.